The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

被引：791

作者：

Kotschy, Andras ^{[1
]}

Szlavik, Zoltan ^{[1
]}

Murray, James ^{[2
]}

Davidson, James ^{[2
]}

Maragno, Ana Leticia ^{[3
]}

Le Toumelin-Braizat, Gaetane ^{[3
]}

Chanrion, Maia ^{[3
]}

Kelly, Gemma L. ^{[4
,5
]}

Gong, Jia-Nan ^{[4
,5
]}

Moujalled, Donia M. ^{[6
]}

Bruno, Alain ^{[3
]}

Sekei, Marton C. ^{[1
]}

Paczal, Attila ^{[1
]}

Szabo, Zoltan B. ^{[1
]}

Sipos, Szabolcs ^{[1
]}

Radics, Gabor ^{[1
]}

Proszenyak, Agnes ^{[1
]}

Balint, Balazs ^{[1
]}

Ondi, Levente ^{[1
]}

Blasko, Gabor ^{[1
]}

Robertson, Alan ^{[2
]}

Surgenor, Allan ^{[2
]}

Dokurno, Pawel ^{[2
]}

Chen, Ijen ^{[2
]}

Matassova, Natalia ^{[2
]}

Smith, Julia ^{[2
]}

Pedder, Christopher ^{[2
]}

Graham, Christopher ^{[2
]}

Studeny, Aurelie ^{[3
]}

Lysiak-Auvity, Gaelle ^{[3
]}

Girard, Anne-Marie ^{[3
]}

Grave, Fabienne ^{[3
]}

Segal, David ^{[4
,5
]}

Riffkin, Chris D. ^{[4
,5
]}

Pomilio, Giovanna ^{[6
]}

Galbraith, Laura C. A. ^{[4
,5
]}

Aubrey, Brandon J. ^{[4
,5
,7
]}

Brennan, Margs S. ^{[4
,5
]}

Herold, Marco J. ^{[4
,5
]}

Chang, Catherine ^{[4
,5
]}

Guasconi, Ghislaine ^{[3
]}

Auquil, Nicolas C. ^{[3
]}

Melchiore, Fabien ^{[8
]}

Guigal-Stephan, Nolwen ^{[8
]}

Lockhart, Brian ^{[8
]}

Colland, Frederic ^{[3
]}

Hickman, John A. ^{[3
]}

Roberts, Andrew W. ^{[4
,5
,9
]}

Huang, David C. S. ^{[4
,5
]}

Wei, Andrew H. ^{[6
,10
]}

机构：

[1] Servier Res Inst Med Chem, H-1031 Budapest, Hungary

[2] Vernalis R&D Ltd, Cambridge CB21 6GB, England

[3] Inst Rech Servier Oncol, R&D Unit, F-78290 Croissy Sur Seine, France

[4] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3052, Australia

[5] Univ Melbourne, Dept Med Biol, Melbourne, Vic 3010, Australia

[6] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia

[7] Royal Melbourne Hosp, Victorian Comprehens Canc Ctr, Dept Clin Haematol & Bone Marrow Transplantat, Melbourne, Vic 3050, Australia

[8] Inst Rech Servier, Biomarker Res Div, F-78290 Croissy Sur Seine, France

[9] Univ Melbourne, Fac Med, Melbourne, Vic 3010, Australia

[10] Alfred Hosp, Dept Clin Haematol, Melbourne, Vic 3004, Australia

[11] Univ Melbourne, Dept Pharmacol & Pharmaceut, Melbourne, Vic 3010, Australia

来源：

NATURE | 2016年 / 538卷 / 7626期

基金：

英国医学研究理事会;

关键词：

ANTI-APOPTOTIC MCL-1; BCL-XL; MULTIPLE-MYELOMA; HIGH-AFFINITY; TUMOR-CELLS; SURVIVAL; PROTEIN; COMBINATION; DEPENDENCY; NAVITOCLAX;

D O I：

10.1038/nature19830

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Avoidance of apoptosis is critical for the development and sustained growth of tumours. The pro-survival protein myeloid cell leukemia 1 (MCL1) is overexpressed in many cancers, but the development of small molecules targeting this protein that are amenable for clinical testing has been challenging. Here we describe S63845, a small molecule that specifically binds with high affinity to the BH3-binding groove of MCL1. Our mechanistic studies demonstrate that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway. In vivo, S63845 shows potent anti-tumour activity with an acceptable safety margin as a single agent in several cancers. Moreover, MCL1 inhibition, either alone or in combination with other anti-cancer drugs, proved effective against several solid cancer-derived cell lines. These results point towards MCL1 as a target for the treatment of a wide range of tumours.

引用

页码：477 / +

页数：20

共 51 条

[1] THE C-MYC ONCOGENE DRIVEN BY IMMUNOGLOBULIN ENHANCERS INDUCES LYMPHOID MALIGNANCY IN TRANSGENIC MICE
ADAMS, JM
HARRIS, AW
PINKERT, CA
CORCORAN, LM
ALEXANDER, WS
CORY, S
PALMITER, RD
BRINSTER, RL
[J]. NATURE, 1985, 318 (6046) : 533 - 538
[2] Mcl-1 is a potential therapeutic target in multiple types of cancer
Akgul, C.
[J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2009, 66 (08) : 1326 - 1336
[3] An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo
Aubrey, Brandon J.
Kelly, Gemma L.
Kueh, Andrew J.
Brennan, Margs S.
O'Connor, Liam
Milla, Liz
Wilcox, Stephen
Tai, Lin
Strasser, Andreas
Herold, Marco J.
[J]. CELL REPORTS, 2015, 10 (08): : 1422 - 1432
[4] The landscape of somatic copy-number alteration across human cancers
Beroukhim, Rameen
Mermel, Craig H.
Porter, Dale
Wei, Guo
Raychaudhuri, Soumya
Donovan, Jerry
Barretina, Jordi
Boehm, Jesse S.
Dobson, Jennifer
Urashima, Mitsuyoshi
Mc Henry, Kevin T.
Pinchback, Reid M.
Ligon, Azra H.
Cho, Yoon-Jae
Haery, Leila
Greulich, Heidi
Reich, Michael
Winckler, Wendy
Lawrence, Michael S.
Weir, Barbara A.
Tanaka, Kumiko E.
Chiang, Derek Y.
Bass, Adam J.
Loo, Alice
Hoffman, Carter
Prensner, John
Liefeld, Ted
Gao, Qing
Yecies, Derek
Signoretti, Sabina
Maher, Elizabeth
Kaye, Frederic J.
Sasaki, Hidefumi
Tepper, Joel E.
Fletcher, Jonathan A.
Tabernero, Josep
Baselga, Jose
Tsao, Ming-Sound
Demichelis, Francesca
Rubin, Mark A.
Janne, Pasi A.
Daly, Mark J.
Nucera, Carmelo
Levine, Ross L.
Ebert, Benjamin L.
Gabriel, Stacey
Rustgi, Anil K.
Antonescu, Cristina R.
Ladanyi, Marc
Letai, Anthony
[J]. NATURE, 2010, 463 (7283) : 899 - 905
[5] Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity
Bruncko, Milan
Wang, Le
Sheppard, George S.
Phillips, Darren C.
Tahir, Stephen K.
Xue, John
Erickson, Scott
Fidanze, Steve
Fry, Elizabeth
Hasvold, Lisa
Jenkins, Gary J.
Jin, Sha
Judge, Russell A.
Kovar, Peter J.
Madar, David
Nimmer, Paul
Park, Chang
Petros, Andrew M.
Rosenberg, Saul H.
Smith, Morey L.
Song, Xiaohong
Sun, Chaohong
Tao, Zhi-Fu
Wang, Xilu
Xiao, Yu
Zhang, Haichao
Tse, Chris
Leverson, Joel D.
Elmore, Steven W.
Souers, Andrew J.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (05) : 2180 - 2194
[6] Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function
Chen, L
Willis, SN
Wei, A
Smith, BJ
Fletcher, JI
Hinds, MG
Colman, PM
Day, CL
Adams, JM
Huang, DCS
[J]. MOLECULAR CELL, 2005, 17 (03) : 393 - 403
[7] Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
Corcoran, Ryan B.
Cheng, Katherine A.
Hata, Aaron N.
Faber, Anthony C.
Ebi, Hiromichi
Coffee, Erin M.
Greninger, Patricia
Brown, Ronald D.
Godfrey, Jason T.
Cohoon, Travis J.
Song, Youngchul
Lifshits, Eugene
Hung, Kenneth E.
Shioda, Toshi
Dias-Santagata, Dora
Singh, Anurag
Settleman, Jeffrey
Benes, Cyril H.
Mino-Kenudson, Mari
Wong, Kwok-Kin
Engelman, Jeffrey A.
[J]. CANCER CELL, 2013, 23 (01) : 121 - 128
[8] Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
Cragg, Mark S.
Jansen, Elisa S.
Cook, Michele
Harris, Claire
Strasser, Andreas
Scott, Clare L.
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (11) : 3651 - 3659
[9] Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Cragg, Mark S.
Harris, Claire
Strasser, Andreas
Scott, Clare L.
[J]. NATURE REVIEWS CANCER, 2009, 9 (05) : 321 - 326
[10] Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, Peter E.
Lessene, Guillaume
Strasser, Andreas
Adams, Jerry M.
[J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2014, 15 (01) : 49 - 63

← 1 2 3 4 5 6 →